New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 22, 2011
09:48 EDTPSS, CHS, SGEN, NFLX, BDGE, SFL, CTRNGappers report: Bearish gaps
This is a list of stocks making unusual moves on the open versus the prior day close. Gapping stocks often have excessive movements during the day and in the days thereafter. We use 5% for filter criteria and scanned for stocks that traded above $10 the prior day. GAPPING DOWN: BDGE (5.57%), CHS (9.04%), PSS (8.32%), NFLX (7.06%), SFL (6.30%), CTRN (6.25%), SGEN (5.13%).
News For BDGE;CHS;CTRN;NFLX;PSS;SFL;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
09:35 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:55 EDTSFLShip Finance reports Q4 EPS 27c, consensus 38c
Subscribe for More Information
07:25 EDTCHSChico's sees FY15 comparable sales increase in positive, low single digits
Subscribe for More Information
07:24 EDTCHSChico's announced organization realignment, eliminates 240 existing positions
The company announced an organizational realignment to ensure that resources are better aligned with long-term growth initiatives, including omni-channel. The changes resulted in the elimination of approximately 240 existing positions, which is expected to result in approximately $38M of annualized savings. The corporate organizational realignment resulted in a 12% reduction of the company's headquarters and field management employee base. In the fourth quarter of 2014, the company recorded pre-tax restructuring charges related to headcount reductions, including severance and other charges, of approximately $8.2M.
07:23 EDTCHSChico's expects to increase rate of domestic store closures
The company expects to close approximately 120 stores starting in fiscal 2015 through 2017. These 120 store closings are expected to ultimately result in expense savings of approximately $55.2 million upon completion. In the fourth quarter of 2014, the company recorded pre-tax impairment charges associated with the accelerated closures of approximately $5.3M. For fiscal 2015, the Company plans to close approximately 35 stores.
07:23 EDTCHSChico's sees FY15 CapEx $100M
Subscribe for More Information
07:22 EDTCHSChico's expects to execute $250M accelerated share repurchase agreement in Q1
At the end of the fourth quarter, the company had $290M remaining under its existing authorization.
07:21 EDTCHSChico's reports Q4 comparable sales growth of 4.3%
Subscribe for More Information
07:20 EDTCHSChico's reports Q4 adjusted EPS 5c, consensus 2c
Reports Q4 revenue $656.91M, consensus $639.93M
February 25, 2015
11:47 EDTNFLXAnalysts clash on DreamWorks following Q4 miss
The shares of animated film and television show maker DreamWorks (DWA) are rising, despite the weaker than expected results reported by the company last night. Two analysts offered very different views on the company's outlook following its results. BACKGROUND: DreamWorks last night reported a fourth quarter per share loss of ($3.08), versus analysts' consensus outlook for a ($3.01) per share loss. The company's revenue also came in below expectations. Excluding $210M in pre-tax charges associated with DreamWorks' restructuring plan, its loss was (75c) per share, the company stated. BEARISH TAKE: In a note to investors today, FBR Capital analyst Barton Crockett wrote that DreamWorks' results were "ugly," as they included $155M of write-offs on films and TV shows. However, Crockett believes that the crucial factor for the company's outlook is whether it can consistently compete with the entertainment giants, including Disney (DIS), Viacom (VIA), and Time Warner (TWX). Crockett is not convinced that DreamWorks will be able to hold its own, and he believes that its 2015 results could come in below expectations. The analyst warned that the company may have difficulty meeting its 2015 consumer products revenue guidance. DreamWorks expects its consumer products revenue to double this year, but the movie-based toy space is "very competitive" in 2015, as toys based on multiple popular children's films are set to be released, Crockett stated. Moreover, after conducting checks online, Crockett reports that there does not seem to be a great deal of interest in DreamWorks' movie "Home," which is set to be released on March 27. He kept an Underperform rating on the shares and raised his price target on the stock to $14 from $12. BULLISH TAKE: DreamWorks' results were mixed, but the results are not very important, Piper Jaffray analyst James Marsh stated. The company's guidance for its TV and consumer products businesses were solid, the analyst believes. Moreover, the company "took specific and decisive action" to avert a liquidity crunch, Marsh wrote. Specifically, DreamWorks raised $185M of capital by selling its real estate in Glendale, California and then leasing it back, and increased the size of its current credit facility to $450M from $400M, Marsh reported. The moves should "largely" eliminate investors' worries about the company's liquidity position, Marsh stated. He kept a $26 price target and Overweight rating on the stock. WHAT'S NOTABLE: On DreamWorks' earnings conference call last night, the company's CEO Jeffrey Katzenberg stated that it did not obtain more than 10% of its revenue from Netflix (NFLX) last year. However, in an SEC filing earlier this morning, DreamWorks clarified that it had obtained 14.9% of its revenue from Netflix last year. PRICE ACTION: In late morning trading, DreamWorks rose 5.6% to $22.31.
11:19 EDTNFLXNetflix to premiere five new shows for kids
Netflix announced that it is adding five new animated and live-action comedy series to its selection of kids and family entertainment. These include Danger Mouse, planned for Spring 2016, Inspector Gadget in March 2015, Some Assembly Required in Summer 2015, Bottersnikes & Gumbles in Spring 2016 and SUPER 4, a new CGI animated series inspired by PLAYMOBIL, which makes its U.S. premiere in April exclusively on Netflix.
09:08 EDTCHSOn The Fly: Pre-market Movers
Subscribe for More Information
06:28 EDTCHSSycamore cancels attempt to buy Chico's, WSJ says
Subscribe for More Information
February 24, 2015
10:01 EDTNFLXNetflix teams up with Judd Apatow for 'Pee-wee's Big Holiday'
Netflix will premiere exclusively in all of its territories the new feature film, Pee-wee's Big Holiday, starring Paul Reubens as the beloved fun-loving hero of TV, stage and film, Pee-wee Herman. Judd Apatow and Reubens, who worked together to bring the project to fruition, will produce the film. Production is slated to begin in early 2015.
09:59 EDTCHSChico's management to meet with Oppenheimer
Subscribe for More Information
07:15 EDTNFLXNetflix may enter Russia within two years, Hollywood Reporter says
Netflix' head of communications in Europe, Joris Evers, says the company hopes to make its entrance in Russia within the next two years, The Hollywood Reporter says. Reference Link
February 19, 2015
16:01 EDTNFLXOptions Update; February 19, 2015
iPath S&P 500 VIX Short-Term Futures down 70c to 30.11. Option volume leaders: AAPL TSLA TWTR AMAT PBR KO FB AXP NFLX according to Track Data.
February 18, 2015
16:00 EDTNFLXOptions Update; February 18, 2015
Subscribe for More Information
09:37 EDTNFLXOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
09:05 EDTSGENSeattle Genetics submits supplemental BLA to FDA for Phase 3 Aethera trial
Seattle Genetics announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration based on data from the phase 3 AETHERA trial of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant in Hodgkin lymphoma patients at high risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT. The supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that were presented at the 56th American Society of Hematology Annual Meeting in December 2014. Results from the AETHERA trial in 329 HL patients at high risk of relapse included: The trial achieved its primary endpoint and demonstrated a significant increase in progression-free survival per independent review facility, with a hazard ratio of 0.57 and a p-value of 0.001. Median PFS was 43 months for patients who received ADCETRIS versus 24 months for patients who received placebo. The two-year PFS rate was 63 percent in the ADCETRIS arm compared to 51 percent in the placebo arm. The PFS benefit was consistent across all pre-specified subgroups, including primary refractory patients, patients who relapsed within twelve months of frontline therapy and patients who relapsed after twelve months with extranodal disease.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use